STAT6 and neoplasm: ASOs selectively silence STAT6 expression in TAM (tumor-associated macrophages), exoASO-STAT6 monotherapy produced an effective anti-tumor response, prompting clinical researchers to start investigating new cancer therapies as effective monotherapy candidates for other types of cancer, including OSCC [117].